FindTrial
Sign In

Efficacy and Safety of Direct Antiviral Agents for Chinese Patients with Chronic Hepatitis C Virus Infection in Real-World Setting

Efficacy and Safety of direct antiviral agents for Chinese patients with chronic hepatitis C virus infection in real-world setting

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014889
Enrollment
Unknown
Registered
2018-02-12
Start date
2018-02-08
Completion date
Unknown
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Case series:direct antiviral agents

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: CHC patients who have received direct antiviral agents treatment, regardless the presence of cirrhosis

Exclusion criteria

Exclusion criteria: 1. Coexisting serious medical condition or advanced liver disease (including decompensated cirrhosis, liver failure, and hepatic carcinoma); 2. No detailed general demographic (such as age, gender and route of HCV infection) and clinical laboratory data (such as routine blood test, biochemical parameters, HCV RNA, alpha-fetoprotein and liver ultrasound).

Design outcomes

Primary

MeasureTime frame
sustained virological response;—

Countries

China

Contacts

Public ContactHong Tang

Center of Infectious Diseases, West China Hospital of Sichuan University

htang6198@hotmail.com+86 028-85422859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026